Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS.

The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...

Continuous variable modeling such as the Hodgkin lymphoma international prognostic index (A-HIPI) improves prognostic ...

Fixed-duration venetoclax regimens showed non-inferior progression-free survival compared to continuous ibrutinib in CLL ...

Families with children treated for ALL often face catastrophic financial toxicity, including severe income loss and inability to afford basic needs. Financial strain typically intensifies six months ...

A recent clinical trial found that a new TROP2-targeted antibody-drug conjugate (ADC) showed encouraging efficacy in treating ...

The decision to use newer agents in relapsed/refractory follicular lymphoma is heavily influenced by the disease’s inherent ...

Antonio Urbina, MD, the medical director for the Mount Sinai Institute for Advanced Medicine 7th Avenue clinic in New York ...

The upcoming American Society of Hematology (ASH) 2025 meeting is poised to spotlight several pivotal developments across ...

Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.

Health care is constantly evolving, and kidney health is no different. Several presentations during the IVBM event addressed ...

Patients with polycythemia vera (PV) taking the investigational therapy rusfertide were able to largely maintain hematocrit control and avoid the need for phlebotomy over 52 weeks, according to ...